@article{05ba21afaad2470cb05c0af262cde79c,
title = "Pembrolizumab (pembro) with paclitaxel (taxol) or capecitabine (cape) as early treatment of metastatic triple-negative breast cancer (mTNBC).",
author = "Page, \{David B.\} and Brie Chun and Joanna Pucilowska and Isaac Kim and Katherine Sanchez and Redmond, \{William L\} and Zhaoyu Sun and Yaping Wu and Alicia Feryn and Maritza Martel and Abaya, \{Christina DiLauro\} and Dottie Wadell and Mellinger, \{Staci L.\} and Nicole Moxon and Urba, \{Walter John\} and Philomena McAndrew and Maryliza El-Masry and Basho, \{Reva K.\} and Conlin, \{Alison Katherine\} and McArthur, \{Heather L.\}",
note = "1015 Background: Atezolizumab (anti-PD-L1) plus nab-paclitaxel was shown to improve outcomes in mTBNC in a phase III clinical trial. Subjects were required to be 12 months from curative-intent therapy in this trial. It remains unknown whether non-taxane chemo + anti-PD-1/L1 will be beneficial in mTNBC, or whether this approach is effective in rapidly-progressing patients ( 12 mo from curative-intent therapy).",
year = "2019",
month = may,
day = "20",
doi = "10.1200/jco.2019.37.15\_suppl.1015",
language = "American English",
volume = "37",
journal = "Journal of Clinical Oncology",
}